The global vaccines market is forecasted to grow by USD 43231.9 mn during 2025-2030, accelerating at a CAGR of 7.2% during the forecast period. The report on the global vaccines market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.
The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by expansion of public health initiatives and national immunization programs, technological advancements in vaccine platforms and manufacturing scalability, rising global emphasis on preventive healthcare and pandemic preparedness.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market size data, segment with regional analysis and vendor landscape in addition to an analysis of the key companies. Reports have historic and forecast data.
| Market Scope |
| Base Year | 2025 |
| End Year | 2030 |
| Series Year | 2026-2030 |
| Growth Momentum | Accelerate |
| YOY 2026 | 6.9% |
| CAGR | 7.2% |
| Incremental Value | $43231.9 mn |
Technavio's global vaccines market is segmented as below:
By Type
- Subunit vaccines
- Live attenuated vaccines
- Inactivated vaccines
- Toxoid vaccines
- Others
By End-User
By Technology
- mRNA vaccines
- Viral vector vaccines
- Protein based vaccines
- DNA vaccines
- Others
By Route Of Administration
- Intramuscular
- Subcutaneous
- Oral
- Intranasal
- Others
By Disease Type
- Influenza
- Human papillomavirus
- Hepatitis
- Measles
- Others
By Age Group
- Pediatric
- Adult
- Adolescent
- Geriatric
Geography
- North America
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Spain
- Asia
- Rest of World (ROW)
- Rest of World (ROW)
This study identifies the accelerated adoption of ai in vaccine design and antigen selection as one of the prime reasons driving the global vaccines market growth during the next few years. Also, proliferation of multivalent and combination formulations to overcome immunization fatigue and localization of manufacturing infrastructure and regional supply chain decentralization will lead to sizable demand in the market.
The report on the global vaccines market covers the following areas:
- Global vaccines market sizing
- Global vaccines market forecast
- Global vaccines market industry analysis
The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading global vaccines market vendors that include AstraZeneca Plc, Bavarian Nordic AS, Bharat Biotech Ltd., BioKangtai, Biological E. Ltd., BioNTech SE, CSL Seqirus, Dynavax Technologies Corp., Emergent BioSolutions Inc., GC Biopharma Corp., GlaxoSmithKline Plc, Inovio Pharmaceuticals Inc., Johnson and Johnson, Merck and Co. Inc., Mitsubishi Tanabe Pharma Corp., Moderna Inc., Novavax Inc., Pfizer Inc., Sanofi SA, Serum Institute of India Ltd., Sinopharm, Takeda Pharmaceutical Ltd., Valneva SE. Also, the global vaccines market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.
The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive primary and secondary research. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.
Table of Contents
1 Executive Summary
- 1.1 Market overview
- Executive Summary - Chart on Market Overview
- Executive Summary - Data Table on Market Overview
- Executive Summary - Chart on Global Market Characteristics
- Executive Summary - Chart on Market by Geography
- Executive Summary - Chart on Market Segmentation by Type
- Executive Summary - Chart on Market Segmentation by End-user
- Executive Summary - Chart on Market Segmentation by Technology
- Executive Summary - Chart on Market Segmentation by Route of Administration
- Executive Summary - Chart on Market Segmentation by Disease Type
- Executive Summary - Chart on Market Segmentation by Age Group
- Executive Summary - Chart on Incremental Growth
- Executive Summary - Data Table on Incremental Growth
- Executive Summary - Chart on Company Market Positioning
2 Technavio Analysis
- 2.1 Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
- Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
- 2.2 Criticality of inputs and Factors of differentiation
- 2.3 Factors of disruption
- 2.4 Impact of drivers and challenges
3 Market Landscape
- 3.1 Market ecosystem
- 3.2 Market characteristics
- 3.3 Value chain analysis
4 Market Sizing
- 4.1 Market definition
- 4.2 Market segment analysis
- 4.3 Market size 2025
- 4.4 Market outlook: Forecast for 2025-2030
5 Historic Market Size
- 5.1 Global Vaccines Market 2020 - 2024
- Historic Market Size - Data Table on Global Vaccines Market 2020 - 2024 ($ million)
- 5.2 Type segment analysis 2020 - 2024
- Historic Market Size - Type Segment 2020 - 2024 ($ million)
- 5.3 End-user segment analysis 2020 - 2024
- Historic Market Size - End-user Segment 2020 - 2024 ($ million)
- 5.4 Technology segment analysis 2020 - 2024
- Historic Market Size - Technology Segment 2020 - 2024 ($ million)
- 5.5 Route of Administration segment analysis 2020 - 2024
- Historic Market Size - Route of Administration Segment 2020 - 2024 ($ million)
- 5.6 Disease Type segment analysis 2020 - 2024
- Historic Market Size - Disease Type Segment 2020 - 2024 ($ million)
- 5.7 Age Group segment analysis 2020 - 2024
- Historic Market Size - Age Group Segment 2020 - 2024 ($ million)
- 5.8 Geography segment analysis 2020 - 2024
- Historic Market Size - Geography Segment 2020 - 2024 ($ million)
- 5.9 Country segment analysis 2020 - 2024
- Historic Market Size - Country Segment 2020 - 2024 ($ million)
6 Qualitative Analysis
- 6.1 Impact of AI on global vaccines market
- 6.2 Impact of geopolitical conflicts on global vaccines market
7 Five Forces Analysis
- 7.1 Five forces summary
- Five forces analysis - Comparison between 2025 and 2030
- 7.2 Bargaining power of buyers
- Bargaining power of buyers - Impact of key factors 2025 and 2030
- 7.3 Bargaining power of suppliers
- Bargaining power of suppliers - Impact of key factors in 2025 and 2030
- 7.4 Threat of new entrants
- Threat of new entrants - Impact of key factors in 2025 and 2030
- 7.5 Threat of substitutes
- Threat of substitutes - Impact of key factors in 2025 and 2030
- 7.6 Threat of rivalry
- Threat of rivalry - Impact of key factors in 2025 and 2030
- 7.7 Market condition
8 Market Segmentation by Type
- 8.1 Market segments
- 8.2 Comparison by Type
- 8.3 Subunit vaccines - Market size and forecast 2025-2030
- 8.4 Live attenuated vaccines - Market size and forecast 2025-2030
- 8.5 Inactivated vaccines - Market size and forecast 2025-2030
- 8.6 Toxoid vaccines - Market size and forecast 2025-2030
- 8.7 Others - Market size and forecast 2025-2030
- 8.8 Market opportunity by Type
- Market opportunity by Type ($ million)
9 Market Segmentation by End-user
- 9.1 Market segments
- 9.2 Comparison by End-user
- 9.3 Hospitals - Market size and forecast 2025-2030
- 9.4 Clinics - Market size and forecast 2025-2030
- 9.5 Market opportunity by End-user
- Market opportunity by End-user ($ million)
10 Market Segmentation by Technology
- 10.1 Market segments
- 10.2 Comparison by Technology
- 10.3 mRNA vaccines - Market size and forecast 2025-2030
- 10.4 Viral vector vaccines - Market size and forecast 2025-2030
- 10.5 Protein based vaccines - Market size and forecast 2025-2030
- 10.6 DNA vaccines - Market size and forecast 2025-2030
- 10.7 Others - Market size and forecast 2025-2030
- 10.8 Market opportunity by Technology
- Market opportunity by Technology ($ million)
11 Market Segmentation by Route of Administration
- 11.1 Market segments
- 11.2 Comparison by Route of Administration
- 11.3 Intramuscular - Market size and forecast 2025-2030
- 11.4 Subcutaneous - Market size and forecast 2025-2030
- 11.5 Oral - Market size and forecast 2025-2030
- 11.6 Intranasal - Market size and forecast 2025-2030
- 11.7 Others - Market size and forecast 2025-2030
- 11.8 Market opportunity by Route of Administration
- Market opportunity by Route of Administration ($ million)
12 Market Segmentation by Disease Type
- 12.1 Market segments
- 12.2 Comparison by Disease Type
- 12.3 Influenza - Market size and forecast 2025-2030
- 12.4 Human papillomavirus - Market size and forecast 2025-2030
- 12.5 Hepatitis - Market size and forecast 2025-2030
- 12.6 Measles - Market size and forecast 2025-2030
- 12.7 Others - Market size and forecast 2025-2030
- 12.8 Market opportunity by Disease Type
- Market opportunity by Disease Type ($ million)
13 Market Segmentation by Age Group
- 13.1 Market segments
- 13.2 Comparison by Age Group
- 13.3 Pediatric - Market size and forecast 2025-2030
- 13.4 Adult - Market size and forecast 2025-2030
- 13.5 Adolescent - Market size and forecast 2025-2030
- 13.6 Geriatric - Market size and forecast 2025-2030
- 13.7 Market opportunity by Age Group
- Market opportunity by Age Group ($ million)
14 Customer Landscape
- 14.1 Customer landscape overview
- Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
15 Geographic Landscape
- 15.1 Geographic segmentation
- 15.2 Geographic comparison
- 15.3 North America - Market size and forecast 2025-2030
- 15.3.1 US - Market size and forecast 2025-2030
- 15.3.2 Canada - Market size and forecast 2025-2030
- 15.3.3 Mexico - Market size and forecast 2025-2030
- 15.4 Europe - Market size and forecast 2025-2030
- 15.4.1 Germany - Market size and forecast 2025-2030
- 15.4.2 France - Market size and forecast 2025-2030
- 15.4.3 UK - Market size and forecast 2025-2030
- 15.4.4 Italy - Market size and forecast 2025-2030
- 15.4.5 Russia - Market size and forecast 2025-2030
- 15.4.6 Spain - Market size and forecast 2025-2030
- 15.5 Asia - Market size and forecast 2025-2030
- 15.5.1 China - Market size and forecast 2025-2030
- 15.5.2 India - Market size and forecast 2025-2030
- 15.5.3 Japan - Market size and forecast 2025-2030
- 15.5.4 South Korea - Market size and forecast 2025-2030
- 15.5.5 Indonesia - Market size and forecast 2025-2030
- 15.5.6 Thailand - Market size and forecast 2025-2030
- 15.6 Rest of World (ROW) - Market size and forecast 2025-2030
- 15.6.1 Brazil - Market size and forecast 2025-2030
- 15.6.2 Saudi Arabia - Market size and forecast 2025-2030
- 15.6.3 South Africa - Market size and forecast 2025-2030
- 15.6.4 Egypt - Market size and forecast 2025-2030
- 15.6.5 UAE - Market size and forecast 2025-2030
- 15.6.6 Argentina - Market size and forecast 2025-2030
- 15.6.7 Colombia - Market size and forecast 2025-2030
- 15.6.8 Nigeria - Market size and forecast 2025-2030
- 15.7 Market opportunity by geography
- Market opportunity by geography ($ million)
- Data Tables on Market opportunity by geography ($ million)
16 Drivers, Challenges, and Opportunity
- 16.1 Market drivers
- Expansion of public health initiatives and national immunization programs
- Technological advancements in vaccine platforms and manufacturing scalability
- Rising global emphasis on preventive healthcare and pandemic preparedness
- 16.2 Market challenges
- Stringent and fragmented regulatory frameworks across divergent jurisdictions
- Vulnerabilities and cold-chain bottlenecks in global distribution infrastructure
- Pervasive vaccine hesitancy amplified by digital misinformation campaigns
- 16.3 Impact of drivers and challenges
- Impact of drivers and challenges in 2025 and 2030
- 16.4 Market opportunities
- Accelerated adoption of AI in vaccine design and antigen selection
- Proliferation of multivalent and combination formulations to overcome immunization fatigue
- Localization of manufacturing infrastructure and regional supply chain decentralization
17 Competitive Landscape
- 17.1 Overview
- 17.2 Competitive Landscape
- Overview on criticality of inputs and factors of differentiation
- 17.3 Landscape disruption
- Overview on factors of disruption
- 17.4 Industry risks
- Impact of key risks on business
18 Competitive Analysis
- 18.1 Companies profiled
- 18.2 Company ranking index
- 18.3 Market positioning of companies
- Matrix on companies position and classification
- 18.4 AstraZeneca Plc
- AstraZeneca Plc - Overview
- AstraZeneca Plc - Business segments
- AstraZeneca Plc - Key news
- AstraZeneca Plc - Key offerings
- AstraZeneca Plc - Segment focus
- SWOT
- 18.5 BioKangtai
- BioKangtai - Overview
- BioKangtai - Product / Service
- BioKangtai - Key offerings
- SWOT
- 18.6 BioNTech SE
- BioNTech SE - Overview
- BioNTech SE - Product / Service
- BioNTech SE - Key offerings
- SWOT
- 18.7 CSL Seqirus
- CSL Seqirus - Overview
- CSL Seqirus - Product / Service
- CSL Seqirus - Key offerings
- SWOT
- 18.8 Emergent BioSolutions Inc.
- Emergent BioSolutions Inc. - Overview
- Emergent BioSolutions Inc. - Product / Service
- Emergent BioSolutions Inc. - Key offerings
- SWOT
- 18.9 GlaxoSmithKline Plc
- GlaxoSmithKline Plc - Overview
- GlaxoSmithKline Plc - Business segments
- GlaxoSmithKline Plc - Key news
- GlaxoSmithKline Plc - Key offerings
- GlaxoSmithKline Plc - Segment focus
- SWOT
- 18.10 Inovio Pharmaceuticals Inc.
- Inovio Pharmaceuticals Inc. - Overview
- Inovio Pharmaceuticals Inc. - Product / Service
- Inovio Pharmaceuticals Inc. - Key offerings
- SWOT
- 18.11 Johnson and Johnson
- Johnson and Johnson - Overview
- Johnson and Johnson - Business segments
- Johnson and Johnson - Key news
- Johnson and Johnson - Key offerings
- Johnson and Johnson - Segment focus
- SWOT
- 18.12 Merck and Co. Inc.
- Merck and Co. Inc. - Overview
- Merck and Co. Inc. - Business segments
- Merck and Co. Inc. - Key news
- Merck and Co. Inc. - Key offerings
- Merck and Co. Inc. - Segment focus
- SWOT
- 18.13 Mitsubishi Tanabe Pharma Corp.
- Mitsubishi Tanabe Pharma Corp. - Overview
- Mitsubishi Tanabe Pharma Corp. - Product / Service
- Mitsubishi Tanabe Pharma Corp. - Key offerings
- SWOT
- 18.14 Moderna Inc.
- Moderna Inc. - Overview
- Moderna Inc. - Product / Service
- Moderna Inc. - Key offerings
- SWOT
- 18.15 Pfizer Inc.
- Pfizer Inc. - Overview
- Pfizer Inc. - Business segments
- Pfizer Inc. - Key news
- Pfizer Inc. - Key offerings
- Pfizer Inc. - Segment focus
- SWOT
- 18.16 Sanofi SA
- Sanofi SA - Overview
- Sanofi SA - Business segments
- Sanofi SA - Key news
- Sanofi SA - Key offerings
- Sanofi SA - Segment focus
- SWOT
- 18.17 Sinopharm
- Sinopharm - Overview
- Sinopharm - Product / Service
- Sinopharm - Key offerings
- SWOT
- 18.18 Takeda Pharmaceutical Ltd.
- Takeda Pharmaceutical Ltd. - Overview
- Takeda Pharmaceutical Ltd. - Business segments
- Takeda Pharmaceutical Ltd. - Key news
- Takeda Pharmaceutical Ltd. - Key offerings
- Takeda Pharmaceutical Ltd. - Segment focus
- SWOT
19 Appendix
- 19.1 Scope of the report
- Market definition
- Objectives
- Notes and caveats
- 19.2 Inclusions and exclusions checklist
- Inclusions checklist
- Exclusions checklist
- 19.3 Currency conversion rates for US$
- Currency conversion rates for US$
- 19.4 Research methodology
- 19.5 Data procurement
- 19.6 Data validation
- 19.7 Validation techniques employed for market sizing
- Validation techniques employed for market sizing
- 19.8 Data synthesis
- 19.9 360 degree market analysis
- 360 degree market analysis
- 19.10 List of abbreviations